open access

Vol 29, No 4 (2022)
Research Letter
Submitted: 2021-10-10
Accepted: 2022-02-21
Published online: 2022-05-13
Get Citation

Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes

Chun-Ka Wong1, Yee-Man Lau1, Wing-Hon Lai1, Ricky-Ruiqi Zhang2, Hayes Kam-Hei Luk3, Antonio Cheuk-Pui Wong3, Patrick Chiu-Yat Woo3, Susanna Kar-Pui Lau3, Kwok-Hung Chan2, Ivan Fan-Ngai Hung2, Chung-Wah Siu1
DOI: 10.5603/CJ.a2022.0033
·
Pubmed: 35578759
·
Cardiol J 2022;29(4):702-706.
Affiliations
  1. Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  2. Infectious Disease Division, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  3. Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

open access

Vol 29, No 4 (2022)
Research letters — COVID-19
Submitted: 2021-10-10
Accepted: 2022-02-21
Published online: 2022-05-13

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes

Journal

Cardiology Journal

Issue

Vol 29, No 4 (2022)

Article type

Research Letter

Pages

702-706

Published online

2022-05-13

Page views

1710

Article views/downloads

308

DOI

10.5603/CJ.a2022.0033

Pubmed

35578759

Bibliographic record

Cardiol J 2022;29(4):702-706.

Authors

Chun-Ka Wong
Yee-Man Lau
Wing-Hon Lai
Ricky-Ruiqi Zhang
Hayes Kam-Hei Luk
Antonio Cheuk-Pui Wong
Patrick Chiu-Yat Woo
Susanna Kar-Pui Lau
Kwok-Hung Chan
Ivan Fan-Ngai Hung
Chung-Wah Siu

References (10)
  1. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7): 811–818.
  2. Liu H, Gai S, Wang X, et al. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Cardiovasc Res. 2020; 116(10): 1733–1741.
  3. Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17(5): 259–260.
  4. Gager GM, Gelbenegger G, Jilma B, et al. Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis. Front Cardiovasc Med. 2021; 8: 691907.
  5. Wong CK, Luk HKH, Lai WH, et al. Human-Induced pluripotent stem cell-derived cardiomyocytes platform to study SARS-CoV-2 related myocardial injury. Circ J. 2020; 84(11): 2027–2031.
  6. Ng KM, Lau YM, Dhandhania V, et al. Empagliflozin ammeliorates high glucose induced-cardiac dysfuntion in human iPSC-derived cardiomyocytes. Sci Rep. 2018; 8(1): 14872.
  7. Wang L, Zhang YL, Lin QY, et al. CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration. Eur Heart J. 2018; 39(20): 1818–1831.
  8. Bean DM, Kraljevic Z, Searle T, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail. 2020; 22(6): 967–974.
  9. Németh ZH, Deitch EA, Lu Qi, et al. NHE blockade inhibits chemokine production and NF-kappaB activation in immunostimulated endothelial cells. Am J Physiol Cell Physiol. 2002; 283(2): C396–C403.
  10. Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na/H exchanger, lowering of cytosolic Na and vasodilation. Diabetologia. 2018; 61(3): 722–726.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl